Early Psychosis: Investigating Cognition

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-55
SponsorUniversity of Nottingham

About this trial

The project aims to explore changes in brain chemistry in individuals who have recently experienced psychosis. Recent research suggests that chemicals in the brain, specifically one called glutamate, may behave differently in people who have experienced psychosis compared to those who have not. It is also known that some individuals with psychosis can find tasks involving memory and attention more challenging. This study aims at understanding how brain chemistry is linked to memory and attention, and if this is different between people who have and have not experienced psychosis.

The study will also investigate how a commonly used brain stimulation technique might help people with psychosis and other conditions by altering brain chemistry for a very short period. Non-invasive brain stimulation using very weak electrical stimulation has been used to help improve symptoms in individuals with psychosis and many other conditions, and has been shown to alter brain chemistry for a few hours after stimulation. However, it does not work for everyone. It will be investigated if levels of glutamate can predict whether brain stimulation will help an individual or not. In other words, the study investigates if glutamate can be used as a marker for tailoring treatments.

This project also aims to collect personal experiences or challenges that individuals with psychosis face. This information will be gathered through interviews. This will help to understand what specific difficulties individuals have, such as with certain aspects of memory and attention. The interview will also gather opinions and concerns about brain imaging and brain stimulation and current understandings of chemicals in the brain. For example, the study will explore why individuals may not want to take part in brain imaging or brain stimulation.

Eligibility criteria

Qualifiers

Aged 18-55 years.

Ability to understand and willing to give written informed consent.

Fluent in English to be able to understand all cognitive task instructions and questionnaires.

Current psychotic disorder of less than 5yrs total duration. Defined as meeting DSM-5 criteria consistent with a diagnosis of schizophrenia, schizoaffective disorder, bipolar affective disorder, or severe depression with psychosis.

Disqualifiers

Clinically significant neurological or comorbid psychiatric disorder in the opinion of the investigator.

History of clinically significant head injury

Current harmful use of, or dependence on, psychoactive substances (excluding nicotine) in the opinion of the investigator

Current use of any medication which may interfere with the study in the opinion of the investigator, i.e. any medication that might affect the neurochemicals of interest

Trial design

Treatments tested in this trial

  • Transcranial direct current stimulation (tDCS)
  • Magnetic Resonance Imaging

Treatment groups

106 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of Nottingham

Lead sponsor

Wellcome Trust

Collaborator